in vivo research
-
September 17, 2024
Beyond Immune Checkpoint Inhibition: Bispecific T-cell Engagers
Introduction
The field of cancer immunotherapy has witnessed remarkable advancements in recent years, with immune checkpoint inhibitors (ICIs) at the forefront of this revolution. However, as the limitations of ICIs become...
-
September 05, 2024
Uncovering Exhausted T Cell Phenotypes in Autoimmune Diseases: The Crucial Role of HLA Blocking Antibodies
Introduction
The latest study about the role of autoantigen-specific CD4+ T cell phenotypes in several autoimmune diseases opens a new...
-
August 26, 2024
Harnessing Anti-CTLA-4 Antibodies for In Vivo Cancer Immunotherapy Models
Introduction
The field of cancer immunotherapy has witnessed remarkable advancements in recent years, with immune checkpoint inhibitors emerging as a revolutionary approach to treating various malignancies. Among...
-
August 21, 2024
Breakthrough in Cancer Immunotherapy: Multiantigen T-Cell Hybridizers Show Promise in Treating Hematological Malignancies
Introduction
A recent revolutionary study in the journal ACS Nano presents a novel immunotherapy approach to treating haematological...
-
August 12, 2024
Targeting Neutrophil Migration as a Therapeutic Strategy for Chronic Inflammatory Diseases
Abstract:
Neutrophils play a critical role in the innate immune response but their dysregulated recruitment and activation can drive tissue damage in chronic inflammatory conditions. This review examines current understanding of the molecular mechanisms regulating... -
August 05, 2024
Targeting Regulatory T Cells In Vivo: A Guide to Using Anti-CD25 Antibodies
Introduction
Regulatory T cells (Tregs) play a crucial role in maintaining immune homeostasis and preventing autoimmunity. However, in certain contexts, such as cancer immunotherapy, the suppressive function of Tregs can hinder effective immune responses against tumors. Targeting... -
August 01, 2024
Harnessing 4-1BB Immunomodulation for Cancer Therapy
Introduction
The tumor necrosis factor receptor superfamily member 9 (TNFRSF9), also known as 4-1BB or CD137, has emerged as a promising target for cancer immunotherapy. This costimulatory receptor, primarily expressed on activated T cells and natural killer (NK) cells, plays a crucial role in enhancing... -
June 06, 2024
Dendritic Cell Depletion In Vivo
1. Introduction
Dendritic cells (DCs) are crucial immune system components, acting as primary antigen-presenting cells that bridge the innate and adaptive immune responses [1]. Depleting dendritic cells in vivo is a standard experimental technique to study...
-
June 05, 2024
1. Understanding CD8+ T Cell Depletion
The fall or removal of CD8+ T cells, a form of T cell depletion, leads to the recognition and eradicating of various abnormal cells, virally infected cells, and tumor cells because CD8+ T cells are essential components of the immune defense system [1]. There are several ways to eliminate T cells, but antibody-based depletion has become a breakthrough in the respective...